Would you use autologous hematopoietic stem cells collected from a HR neuroblastoma patient found to be COVID positive after harvest?

While the safest approach might be to try to do another collection once the patient has recovered, that may not be feasible or lead to delays in the transplant. I would use this product since transmission of SARS-CoV-2 is not systematic and there is no evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors. In addition, Leclerc et al., PMID 33539769 described two allogeneic transplants from SARS-CoV-2 positive donors and neither of them developed an infection.

Corman et al., PMID 32361996.

Kwon et al., PMID 32240537.

Chen et al., PMID 32151335.